Synapse - Single-Agent Mosunetuzumab Produces High Complete Response Rates in Patients with Newly Diagnosed Follicular Lymphoma: Primary Analysis of the Mithic-FL1 Trial

Single-Agent Mosunetuzumab Produces High Complete Response Rates in Patients with Newly Diagnosed Follicular Lymphoma: Primary Analysis of the Mithic-FL1 Trial Meeting Abstract

Authors:	Falchi, L.; Okwali, M.; Lopes, A. F.; Hamlin, P. A.; Lue, J. K.; Ghione, P.; Owens, C.; Torka, P.; Kumar, A.; Steiner, R.; Epstein-Peterson, Z. D.; Palomba, M. L.; Stuver, R.; Noy, A.; Martinova, A.; Wood, L.; Grieve, C.; Amador, W. R.; Vardhana, S. A.; Zelenetz, A. D.; Leslie, L. A.; Roswarski, J. L.; Dunleavy, K.; Goy, A.; Salles, G.
Abstract Title:	Single-Agent Mosunetuzumab Produces High Complete Response Rates in Patients with Newly Diagnosed Follicular Lymphoma: Primary Analysis of the Mithic-FL1 Trial
Meeting Title:	Blood
Journal Title:	Blood
Volume:	144
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2024-11-01
Start Page:	341
End Page:	341
Language:	English
ACCESSION:	WOS:001412768200040
DOI:	10.1182/blood-2024-205046
PROVIDER:	wos
Notes:	Meeting Abstract -- 66th Annual Meeting of the American-Society-of-Hematology (ASH) -- DEC 06-09, 2025 -- 1 -- Orlando, FL -- Source: Wos